Maria Cristina Campopiano, Arianna Ghirri, Alessandro Prete, Loredana Lorusso, Luciana Puleo, Virginia Cappagli, Laura Agate, Valeria Bottici, Sandra Brogioni, Carla Gambale, Elisa Minaldi, Antonio Matrone, Rossella Elisei, Eleonora Molinaro
Currently, the differentiated thyroid cancer (DTC) management is shifted toward a tailored approach based on the estimated risks of recurrence and disease-specific mortality. While the current recommendations on the management of metastatic and progressive DTC are clear and unambiguous, the management of slowly progressive or indeterminate disease varies according to different centers and different physicians. In this context, active surveillance (AS) becomes the main tool for clinicians, allowing them to plan a personalized therapeutic strategy, based on the risk of an unfavorable prognosis, and to avoid unnecessary treatment...
2023: Frontiers in Endocrinology